The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775.
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Eisai; Karyopharm Therapeutics; Merck
Other Relationship - IBM
 
Nicoletta Colombo
Employment - Sarepta Therapeutics (I)
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro
 
Alessandro Santin
Consulting or Advisory Role - Merck; Tesaro
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Merck (Inst); Puma Biotechnology (Inst); R-Pharm (Inst); Tesaro (Inst)
 
David Scott Miller
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Asymmetric Therapeutics; BOSTON BIOMEDICAL RESEARCH INSTITUTE; Clinical Education Alliance; Eisai; Eisai; EMD Serono; GlaxoSmithKline; GlaxoSmithKline; Immunogen; Incyte; Incyte; ITeos Therapeutics; Karyopharm Therapeutics; Merck Sharp & Dohme; Myriad Genetic Laboratories; Novartis; Novocure; Seagen; Tarveda Therapeutics
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Akeso Biopharma (Inst); Aprea AB (Inst); AstraZeneca (Inst); EMD Serono; Immunogen (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); NVision (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Zeria Pharmaceutical
Consulting or Advisory Role - Eisai; Genmab; MSD; NanoCarrier; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Genmab (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Merck KGaA (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Seagen (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - MSD
 
Sandro Pignata
Consulting or Advisory Role - AstraZeneca
Research Funding - Clovis Oncology; GlaxoSmithKline; MSD; MSD (Inst); Roche
 
Isabelle Laure Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; DECIPHERA; Genmab; GlaxoSmithKline; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; BMS; Bristol-Myers Squibb; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Macrogenics; Mersana; MSD Oncology; Novartis; Novocure; Pfizer; PharmaMar; Roche; Seagen; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Yong Man Kim
No Relationships to Disclose
 
Eva M. Guerra
Consulting or Advisory Role - AstraZeneca/Merck; Clovis Oncology; MSD; PharmaMar; Tesaro/GSK
Speakers' Bureau - AstraZeneca/Merck; Clovis Oncology; MSD; PharmaMar; Roche; Tesaro/GSK
Expert Testimony - AstraZeneca/Merck; Clovis Oncology; PharmaMar; Roche; Tesaro/GSK
Travel, Accommodations, Expenses - Baxter; Roche; Tesaro/GSK
 
Jie Huang
Employment - Eisai
Stock and Other Ownership Interests - in mutual fund
 
Gianmaria Barresi
Employment - Boehringer Ingelheim; MSD; Pfizer
 
Jodi McKenzie
Employment - Eisai
 
Domenica Lorusso
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Genmab; GlaxoSmithKline; Immunogen; Merck Serono; MSD; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; GlaxoSmithKline; PharmaMar; Roche
(OPTIONAL) Uncompensated Relationships - Gynecological Cancer InterGroup